Amneal Pharmaceuticals, Inc. has completed its acquisition of Kashiv BioSciences, LLC, bringing the two companies together to create a more integrated biosimilars business.
The combination gives Amneal capabilities across the full biosimilars value chain, including research, development, manufacturing and commercialization. The company said the deal creates one of the industry’s few fully integrated biosimilars platforms.
For Amneal, the acquisition is expected to make biosimilars an important long-term part of its affordable medicines business.
Kashiv Adds Research and Manufacturing Capabilities
Kashiv BioSciences brings experience in biologics research, development and manufacturing.
Amneal already has commercial scale and established capabilities for bringing medicines to market. By combining these strengths with Kashiv’s biologics platform, the company expects to have greater control over the development and manufacturing of biosimilar medicines.
This integrated model can also help Amneal prepare multiple products for launch instead of depending on a single biosimilar opportunity.
Amneal Targets More Biosimilar Launches
The company expects the combined business to support a regular flow of biosimilar launches over the coming years.
Chirag Patel, co-founder and co-chief executive officer of Amneal, said the acquisition is an important step in the company’s plan to become America’s number one affordable medicines company.
He said the combined business is designed to support the launch of multiple biosimilars each year and extend Amneal’s growth opportunities into the next decade.
Growing Opportunity as Biologic Patents Expire
A major reason behind the acquisition is the growing number of biologic medicines expected to lose market exclusivity.
Amneal said more than $300 billion in global biologics sales are projected to face loss of exclusivity over the next decade.
When biologic medicines lose exclusivity, biosimilars can enter the market and provide additional treatment options. These medicines are highly similar to already approved biologics and can help increase competition and access.
Amneal believes this upcoming wave of biologic loss of exclusivity creates a significant opportunity for its expanded biosimilars business.
Focus on Affordable Biologic Medicines
The acquisition also fits into Amneal’s broader focus on affordable medicines.
Chintu Patel, co-founder and co-chief executive officer of Amneal, said the company expects the combination to help it take advantage of the growing biosimilars opportunity while expanding access to high-quality and affordable biologic medicines.
The company also welcomed the Kashiv team following the completion of the transaction.
Combined Portfolio Supports Long-Term Growth
The combined portfolio is expected to give Amneal a pipeline capable of supporting biosimilar launches for years to come.
Instead of treating biosimilars as a small part of its business, Amneal now plans to make the segment a major growth pillar within its affordable medicines operations.
The company will bring together Kashiv’s biologics development and manufacturing capabilities with its own commercial infrastructure and market reach.
This gives Amneal an end-to-end platform covering the process from early research and development through manufacturing and eventually commercialization.
What the Acquisition Means for the Biosimilars Market
The deal comes at a time when the global biosimilars market is becoming increasingly important.
As more major biologic medicines approach the end of their exclusivity periods, pharmaceutical companies are looking to develop biosimilars that can enter these markets.
For Amneal, having research, development, manufacturing and commercial capabilities under one business could allow it to respond to these opportunities more efficiently.
The company expects the combined platform to support a consistent cadence of biosimilar launches and create a broader growth base for the coming decade.,
